Bristol-Myers Squibb
$58.169876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$58.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.35 (+2.37%) Today
-$0.09 (-0.15%) As of 7:41 AM EDT after-hours
Why Robinhood?
You can buy or sell BMY and other stocks, options, ETFs, and crypto commission-free!
About BMY
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. Read More The company was founded in August 1933 and is headquartered in New York, NY.
Employees
30,000
Headquarters
New York, New York
Founded
1933
Market Cap
131.79B
Price-Earnings Ratio
28.33
Dividend Yield
3.16
Average Volume
20.16M
High Today
$58.73
Low Today
$56.36
Open Price
$57.18
Volume
15.27M
52 Week High
$68.34
52 Week Low
$42.48
Collections
BMY News
ReutersApr 8
BRIEF-Bristol Myers Squibb Announces Acceptance Of U.S., EU Regulatory Filings For Opdivo Plus Yervoy Combined With Limited Chemotherapy In First-Line Lung Cancer
April 8 (Reuters) - Bristol-Myers Squibb Co:
* BRISTOL MYERS SQUIBB ANNOUNCES ACCEPTANCE OF U.S. AND EU REGULATORY FILINGS FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (
Analyst Ratings
63%
of 16 ratings
Buy
63%
Hold
38%
Sell
0%
BMY Earnings
$0.00
$0.41
$0.81
$1.22
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Available May 7, Pre-Market